161 related articles for article (PubMed ID: 23139119)
1. Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk.
Bae ON
Arch Pharm Res; 2012 Oct; 35(10):1693-9. PubMed ID: 23139119
[TBL] [Abstract][Full Text] [Related]
2. An anti-von Willebrand factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial thrombosis.
Arzamendi D; Dandachli F; Théorêt JF; Ducrocq G; Chan M; Mourad W; Gilbert JC; Schaub RG; Tanguay JF; Merhi Y
Clin Appl Thromb Hemost; 2011; 17(6):E70-8. PubMed ID: 21078615
[TBL] [Abstract][Full Text] [Related]
3. Targeting von Willebrand factor and platelet glycoprotein Ib receptor.
Firbas C; Siller-Matula JM; Jilma B
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1689-701. PubMed ID: 21108551
[TBL] [Abstract][Full Text] [Related]
4. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction.
Spiel AO; Mayr FB; Ladani N; Wagner PG; Schaub RG; Gilbert JC; Jilma B
Platelets; 2009 Aug; 20(5):334-40. PubMed ID: 19637097
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of the interaction between von Willebrand factor and platelet GPIb/IX/V.
Gresele P; Momi S
Handb Exp Pharmacol; 2012; (210):287-309. PubMed ID: 22918736
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779.
Diener JL; Daniel Lagassé HA; Duerschmied D; Merhi Y; Tanguay JF; Hutabarat R; Gilbert J; Wagner DD; Schaub R
J Thromb Haemost; 2009 Jul; 7(7):1155-62. PubMed ID: 19422452
[TBL] [Abstract][Full Text] [Related]
7. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo.
Mayr FB; Knöbl P; Jilma B; Siller-Matula JM; Wagner PG; Schaub RG; Gilbert JC; Jilma-Stohlawetz P
Transfusion; 2010 May; 50(5):1079-87. PubMed ID: 20070617
[TBL] [Abstract][Full Text] [Related]
8. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
[TBL] [Abstract][Full Text] [Related]
9. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura.
Jilma-Stohlawetz P; Gilbert JC; Gorczyca ME; Knöbl P; Jilma B
Thromb Haemost; 2011 Sep; 106(3):539-47. PubMed ID: 21833442
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura.
Jilma-Stohlawetz P; Gorczyca ME; Jilma B; Siller-Matula J; Gilbert JC; Knöbl P
Thromb Haemost; 2011 Mar; 105(3):545-52. PubMed ID: 21174003
[TBL] [Abstract][Full Text] [Related]
11. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.
Jilma-Stohlawetz P; Knöbl P; Gilbert JC; Jilma B
Thromb Haemost; 2012 Aug; 108(2):284-90. PubMed ID: 22740102
[TBL] [Abstract][Full Text] [Related]
12. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura.
Knöbl P; Jilma B; Gilbert JC; Hutabarat RM; Wagner PG; Jilma-Stohlawetz P
Transfusion; 2009 Oct; 49(10):2181-5. PubMed ID: 19538431
[TBL] [Abstract][Full Text] [Related]
13. Effects of ticlopidine on von Willebrand factor-mediated shear-induced platelet activation and aggregation.
Goto S; Tamura N; Sakakibara M; Ikeda Y; Handa S
Platelets; 2001 Nov; 12(7):406-14. PubMed ID: 11674857
[TBL] [Abstract][Full Text] [Related]
14. Novel antiplatelet activity of protocatechuic acid through the inhibition of high shear stress-induced platelet aggregation.
Kim K; Bae ON; Lim KM; Noh JY; Kang S; Chung KY; Chung JH
J Pharmacol Exp Ther; 2012 Dec; 343(3):704-11. PubMed ID: 22984226
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels.
Nimjee SM; Dornbos D; Pitoc GA; Wheeler DG; Layzer JM; Venetos N; Huttinger A; Talentino SE; Musgrave NJ; Moody H; Rempel RE; Jones C; Carlisle K; Wilson J; Bratton C; Joseph ME; Khan S; Hoffman MR; Sommerville L; Becker RC; Zweier JL; Sullenger BA
Mol Ther; 2019 Jul; 27(7):1228-1241. PubMed ID: 30987839
[TBL] [Abstract][Full Text] [Related]
16. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.
Gilbert JC; DeFeo-Fraulini T; Hutabarat RM; Horvath CJ; Merlino PG; Marsh HN; Healy JM; Boufakhreddine S; Holohan TV; Schaub RG
Circulation; 2007 Dec; 116(23):2678-86. PubMed ID: 18025536
[TBL] [Abstract][Full Text] [Related]
17. ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent.
Cosmi B
Curr Opin Mol Ther; 2009 Jun; 11(3):322-8. PubMed ID: 19479665
[TBL] [Abstract][Full Text] [Related]
18. [High shear stress induced platelet aggregation (h-SIPA) and effects of antiplatelet therapy].
Isaka N; Tanigawa T; Nishikawa M; Nakano T
Nihon Rinsho; 1998 Oct; 56(10):2624-9. PubMed ID: 9796329
[TBL] [Abstract][Full Text] [Related]
19. Fc-receptor dependent platelet aggregation induced by monoclonal antibodies against platelet glycoprotein Ib or von Willebrand factor.
Cauwenberghs N; Schlammadinger A; Vauterin S; Cooper S; Descheemaeker G; Tornai I; Deckmyn H
Thromb Haemost; 2001 Apr; 85(4):679-85. PubMed ID: 11341505
[TBL] [Abstract][Full Text] [Related]
20. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor.
Kageyama S; Yamamoto H; Nagano M; Arisaka H; Kayahara T; Yoshimoto R
Br J Pharmacol; 1997 Sep; 122(1):165-71. PubMed ID: 9298543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
